Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells
Journal of Molecular Cell Biology · 2024
DOI: 10.1093/jmcb/mjad067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Cell Biology, 2024. Verfasst von Yixian Guo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Colorectal Neoplasms, Receptors, Tumor Necrosis Factor, Type II, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovative Research Team of High-level Local University in Shanghai.
Abstract (Originalsprache)
The enrichment of regulatory T cells (Tregs) in the tumour microenvironment (TME) has been recognized as one of the major factors in the initiation and development of resistance to immune checkpoint inhibitors. C–C motif chemokine receptor 8 (CCR8), a marker of activated suppressive Tregs, has a significant impact on the functions of Tregs in the TME. However, the regulatory mechanism of CCR8 in Tregs remains unclear. Here, we revealed that a high level of TNF-α in the colorectal cancer (CRC) microenvironment upregulated CCR8 expression in Tregs via the TNFR2/NF-κB signalling pathway and the FOXP3 transcription factor. Furthermore, in both anti-programmed cell death protein 1 (anti-PD1)-responsive and anti-PD1-unresponsive tumour models, PD1 blockade induced CCR8+ Treg infiltration. In both models, Tnfr2 depletion or TNFR2 blockade suppressed tumour progression by reducing CCR8+ Treg infiltration and thus augmented the efficacy of anti-PD1 therapy. Finally, we identified that TNFR2+CCR8+ Tregs but not total Tregs were positively correlated with adverse prognosis in patients with CRC and gastric cancer. Our work reveals the regulatory mechanisms of CCR8 in Tregs and identifies TNFR2 as a promising target for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine Shanghai 200025, China.
- Biotheus Inc., Zhuhai 519080, China.
- Department of Pathology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
ORCID-Profile: Hong Lu
Förderung
- National Natural Science Foundation of China
- Innovative Research Team of High-level Local University in Shanghai
Zitieren
APA
Guo, Y., Xie, F., Liu, X., Ke, S., Chen, J., Zhao, Y., Li, N., Wang, Z., Yi, G., Shen, Y., Li, D., Zhu, C., Zhang, Z., Zhao, G., Lu, H., Li, B., & Zhao, W. (2024). Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjad067
Vancouver
Guo Y, Xie F, Liu X, Ke S, Chen J, Zhao Y, et al. Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells. Journal of Molecular Cell Biology. 2024. doi:10.1093/jmcb/mjad067
BibTeX
@article{Guo2024,
author = {Guo, Yixian and Xie, Feng and Liu, Xu and Ke, Shouyu and Chen, Jieqiong and Zhao, Yi and Li, Ning and Wang, Zeyu and Yi, Gang and Shen, Yanying and Li, Dan and Zhu, Chunchao and Zhang, Zizhen and Zhao, Gang and Lu, Hong and Li, Bin and Zhao, Wenyi},
title = {Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells},
journal = {Journal of Molecular Cell Biology},
year = {2024},
doi = {10.1093/jmcb/mjad067}
}
EUVIMED